Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Other Non Operating Income (2017 - 2024)

Historic Other Non Operating Income for Aclaris Therapeutics (ACRS) over the last 8 years, with Q2 2024 value amounting to $1.9 million.

  • Aclaris Therapeutics' Other Non Operating Income fell 1682.99% to $1.9 million in Q2 2024 from the same period last year, while for Jun 2024 it was $8.4 million, marking a year-over-year increase of 3128.73%. This contributed to the annual value of $8.5 million for FY2023, which is 18883.23% up from last year.
  • Aclaris Therapeutics' Other Non Operating Income amounted to $1.9 million in Q2 2024, which was down 1682.99% from $2.0 million recorded in Q1 2024.
  • Aclaris Therapeutics' 5-year Other Non Operating Income high stood at $2.3 million for Q3 2023, and its period low was -$851000.0 during Q3 2021.
  • Moreover, its 5-year median value for Other Non Operating Income was $320000.0 (2020), whereas its average is $763722.2.
  • Per our database at Business Quant, Aclaris Therapeutics' Other Non Operating Income tumbled by 33865.98% in 2021 and then skyrocketed by 152247.19% in 2022.
  • Over the past 5 years, Aclaris Therapeutics' Other Non Operating Income (Quarter) stood at -$219000.0 in 2020, then surged by 140.64% to $89000.0 in 2021, then soared by 1522.47% to $1.4 million in 2022, then skyrocketed by 51.59% to $2.2 million in 2023, then fell by 14.66% to $1.9 million in 2024.
  • Its Other Non Operating Income stands at $1.9 million for Q2 2024, versus $2.0 million for Q1 2024 and $2.2 million for Q4 2023.